Innate Pharma (NASDAQ:IPHA) Upgraded at Leerink Partners

Leerink Partners upgraded shares of Innate Pharma (NASDAQ:IPHA) from a market perform rating to an outperform rating in a report released on Tuesday, MarketBeat.com reports. The firm currently has $4.00 target price on the stock.

Several other equities analysts have also commented on IPHA. HC Wainwright upped their price target on Innate Pharma from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings upgraded shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th. Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday. Finally, UBS Group reaffirmed a “buy” rating on shares of Innate Pharma in a research note on Tuesday. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Innate Pharma currently has an average rating of “Moderate Buy” and an average target price of $6.67.

Innate Pharma Trading Up 2.8%

Shares of Innate Pharma stock opened at $2.54 on Tuesday. The stock has a 50 day moving average of $1.83 and a 200 day moving average of $1.68. Innate Pharma has a fifty-two week low of $1.17 and a fifty-two week high of $2.71.

Institutional Investors Weigh In On Innate Pharma

Several institutional investors and hedge funds have recently modified their holdings of IPHA. Jane Street Group LLC purchased a new stake in Innate Pharma during the fourth quarter worth about $162,000. Millennium Management LLC purchased a new stake in shares of Innate Pharma during the fourth quarter worth $36,000. Finally, OLD Mission Capital LLC purchased a new stake in shares of Innate Pharma during the fourth quarter worth $50,000. Hedge funds and other institutional investors own 0.16% of the company’s stock.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.